Dimerix Limited (ASX:DXB)

Market Cap	318.21M
Revenue (ttm)	5.59M
Net Income (ttm)	-13.25M
Shares Out	600.40M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,098,979
Average Volume	743,323
Open	0.5200
Previous Close	0.5300
Day's Range	0.5200 - 0.5450
52-Week Range	0.3000 - 0.7850
Beta	0.17
RSI	61.47
Earnings Date	Nov 23, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.